Drugmaker Shenzhen Hepalink Pharmaceutical Co. Ltd. (002399.CN) said in a regulatory filing Sunday that it planned to acquire US-based heparin producer SPL Acquisition Corp. through its wholly owned unit Hepalink USA Inc., the Securities Times reported Monday. Hepalink has offered to pay about US$223 million in cash for the target’s assets and another US$108 million to its debtors. The acquisition will be partly funded by capital raised in its initial public offering last year, the report said.
– Contact HKEJ [email protected]
TL/AC/SK
